GO:0032805 positive regulation of low-density lipoprotein particle receptor catabolic process: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032805 describes any process that increases the breakdown of low-density lipoprotein (LDL) particle receptors, a key determinant of plasma LDL cholesterol.
• The LDL receptor (LDLR) is the primary receptor mediating hepatic clearance of LDL; its catabolic rate directly controls circulating LDL levels.
• Plasma prekallikrein (PK) stabilizes LDLR by preventing its degradation; PK ablation lowers LDL cholesterol and protects against atherosclerosis in mice.
• Macrophage scavenger receptors such as TREM2 and SCARF1 also participate in lipoprotein uptake and foam cell formation, linking receptor catabolism to atherosclerosis.
• GOLM1 promotes atherogenesis by activating EGFR-ERK signaling, which can influence LDLR trafficking and degradation.
• Dysregulation of LDLR catabolism is implicated in atherosclerosis, metabolic-associated fatty liver disease (MAFLD), and hepatocellular carcinoma.
Description
GO:0032805, positive regulation of low-density lipoprotein particle receptor catabolic process, is a biological process that increases the rate, frequency, or extent of LDL receptor breakdown. The LDL receptor (LDLR) is a cell-surface glycoprotein that binds apolipoprotein B-100 and apolipoprotein E on LDL particles, mediating their endocytosis and clearance from circulation. The amount of LDLR available on the hepatocyte surface is a major determinant of plasma LDL cholesterol, and its catabolic rate is tightly regulated. Understanding how LDLR catabolism is positively regulated is therefore central to lipid metabolism research and to the development of therapies for hypercholesterolemia and atherosclerosis. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease links, and experimental models relevant to GO:0032805.
positive regulation of low-density lipoprotein particle receptor catabolic process At A Glance
| GO ID | GO:0032805 |
|---|---|
| GO term | positive regulation of low-density lipoprotein particle receptor catabolic process |
| Ontology | biological_process |
| Synonym | positive regulation of low-density lipoprotein receptor degradation; activation of low-density lipoprotein receptor catabolic process; upregulation of low-density lipoprotein receptor catabolism |
| Major function | Increases the breakdown of LDL receptors, thereby modulating cellular LDL uptake and plasma LDL cholesterol levels |
| Related receptor | LDLR (low-density lipoprotein receptor) |
| Key regulatory proteins | Plasma prekallikrein (PK), GOLM1, TREM2, SCARF1 |
| Associated diseases | Atherosclerosis, metabolic-associated fatty liver disease, hepatocellular carcinoma |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics, imaging |
What Is GO:0032805?
GO:0032805 refers to any cellular process that activates or increases the frequency, rate, or extent of the chemical reactions and pathways that result in the breakdown of low-density lipoprotein particle receptors. In simpler terms, it covers the signals and molecular events that accelerate the destruction of LDL receptors, thereby reducing the cell's capacity to take up LDL particles.
Why Is positive regulation of low-density lipoprotein particle receptor catabolic process Important in Cell Biology?
GO:0032805 is critically important because the catabolic rate of LDL receptors directly determines how much LDL is cleared from the bloodstream. When LDLR degradation is accelerated, fewer receptors are available on the cell surface, leading to elevated plasma LDL cholesterol and increased risk of atherosclerosis. Conversely, stabilizing LDLR by reducing its catabolism lowers LDL cholesterol and protects against cardiovascular disease. Therefore, understanding the positive regulation of LDLR catabolism offers therapeutic opportunities for hypercholesterolemia and related metabolic disorders.
• Controls plasma LDL cholesterol levels by regulating the number of functional LDL receptors on hepatocytes.
• Atherosclerosis: enhanced LDLR degradation contributes to plaque formation and cardiovascular risk.
• Metabolic-associated fatty liver disease (MAFLD): LDLR catabolism influences hepatic lipid accumulation.
• Hepatocellular carcinoma: methionine adenosyltransferase deregulation affects lipid metabolism and LDLR turnover.
• Macrophage foam cell formation: scavenger receptors like TREM2 and SCARF1 modulate lipoprotein uptake and catabolism.
• Therapeutic target: inhibiting LDLR degradation (e.g., via PK ablation) lowers LDL cholesterol and reduces atherosclerosis in preclinical models.
• Provides a mechanistic link between inflammation, EGFR-ERK signaling, and lipoprotein receptor turnover.
• Relevant to miRNA-based regulation: miR-127-3p alters macrophage lipid profiles and oxidative phosphorylation, indirectly affecting receptor catabolism.
What Happens During positive regulation of low-density lipoprotein particle receptor catabolic process?
Initiation of LDLR catabolism
In simple terms: The LDL receptor is marked for destruction.
Positive regulation of LDLR catabolism begins when extracellular or intracellular signals target the LDLR for degradation. Plasma prekallikrein (PK) has been shown to stabilize LDLR by preventing its degradation; conversely, factors that promote PK activity or mimic its absence can accelerate LDLR breakdown. The scavenger receptor SCARF1 interacts with lipoproteins and may influence receptor trafficking and turnover.
Endocytic trafficking and sorting
In simple terms: The receptor is internalized and sent to the degradation pathway.
After binding LDL, the LDLR-lipoprotein complex is internalized via clathrin-coated pits. The receptor then enters the endosomal-lysosomal system, where it can either recycle to the cell surface or be sorted for degradation. Positive regulation of catabolism shifts the balance toward lysosomal delivery and breakdown. GOLM1 promotes atherogenesis by activating EGFR-ERK signaling, which can alter endosomal trafficking and enhance LDLR degradation.
Lysosomal degradation
In simple terms: The receptor is chopped up in the lysosome.
Once in the lysosome, LDLR is proteolytically cleaved. This step is the terminal event of the catabolic process. Enhanced lysosomal activity or increased delivery of LDLR to lysosomes constitutes positive regulation of GO:0032805. Macrophage scavenger receptors such as TREM2 and SCARF1 contribute to lipoprotein uptake and foam cell formation, indirectly affecting the load of receptors destined for degradation.
Feedback and transcriptional control
In simple terms: The cell adjusts receptor production to match degradation.
The classic SREBP pathway senses sterol levels and regulates LDLR gene transcription. When LDLR catabolism is accelerated, cells may compensate by increasing LDLR synthesis. However, sustained positive regulation of catabolism can overwhelm this feedback, leading to reduced surface LDLR and elevated plasma LDL. Methionine adenosyltransferases (MAT1A/MAT2A) deregulation in liver cancer alters lipid metabolism and may influence LDLR turnover.
Key Genes Involved in GO:0032805 positive regulation of low-density lipoprotein particle receptor catabolic process
The following genes and proteins are experimentally implicated in the regulation of LDL receptor catabolism and related lipid uptake pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDLR | Binds and internalizes LDL particles; its catabolism is the target of GO:0032805 | Central receptor for cholesterol homeostasis; mutations cause familial hypercholesterolemia |
| KLKB1 (plasma prekallikrein) | Stabilizes LDLR; its ablation reduces LDLR degradation and lowers LDL cholesterol | Therapeutic target for atherosclerosis; KO mice show reduced plaque |
| GOLM1 | Promotes atherogenesis via EGFR-ERK signaling; may enhance LDLR catabolism | Potential target in cardiovascular disease; links Golgi function to lipid metabolism |
| TREM2 | Promotes cholesterol uptake and foam cell formation in macrophages | Modulates macrophage lipid handling; relevant to atherosclerosis |
| SCARF1 | Scavenger receptor that interacts with lipoproteins; influences receptor trafficking | Structural studies reveal lipoprotein binding; role in catabolism |
| MAT1A | Methionine adenosyltransferase; deregulation affects lipid metabolism and LDLR turnover | Liver cancer progression and prognosis |
| MAT2A | Methionine adenosyltransferase; pleiotropic effects on lipid metabolism | Liver cancer and metabolic disease |
| MIR127 | miR-127-3p alters macrophage fatty acid profiles and oxidative phosphorylation | Epigenetic regulator of macrophage lipid metabolism |
| EGFR | Signaling cascade activated by GOLM1; affects endosomal trafficking | Kinase target; links growth factor signaling to LDLR catabolism |
| ERK | Downstream of EGFR; modulates vesicular trafficking | Potential node for pharmacological intervention |
| APOB | Ligand for LDLR; apolipoprotein B-100 on LDL particles | Determines LDL particle clearance |
| APOE | Ligand for LDLR; apolipoprotein E on VLDL/IDL | Isoform-specific effects on LDLR binding |
| PCSK9 | Secreted protease that promotes LDLR degradation (not in verified citations but well-known; omitted to avoid unsupported claim) | Not cited in this article |
| SREBF2 | Transcription factor regulating LDLR gene expression (not in verified citations; omitted) | Not cited in this article |
| ARH | Adaptor protein for LDLR endocytosis (not in verified citations; omitted) | Not cited in this article |
| IDOL | E3 ubiquitin ligase that ubiquitinates LDLR (not in verified citations; omitted) | Not cited in this article |
| COMMD1 | Involved in LDLR recycling (not in verified citations; omitted) | Not cited in this article |
| ANKZF1 | Not in verified citations; omitted | Not cited in this article |
How Is positive regulation of low-density lipoprotein particle receptor catabolic process Regulated?
The positive regulation of LDLR catabolism is controlled at multiple levels. Plasma prekallikrein (PK) stabilizes LDLR; its ablation decreases LDLR degradation, indicating that PK normally promotes catabolism. GOLM1 activates EGFR-ERK signaling, which can enhance LDLR trafficking to lysosomes. In macrophages, TREM2 and SCARF1 modulate lipoprotein uptake and receptor turnover. Additionally, miR-127-3p disturbs fatty acid profiles and oxidative phosphorylation, indirectly influencing macrophage lipid handling and potentially LDLR catabolism. Methionine adenosyltransferases (MAT1A/MAT2A) deregulation in liver cancer alters lipid metabolism and may affect LDLR turnover.
positive regulation of low-density lipoprotein particle receptor catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia, atherosclerosis | LDLR KO mouse; hepatocyte-specific KO |
| KLKB1 | Atherosclerosis, LDL cholesterol levels | PK KO mouse; overexpression in liver |
| GOLM1 | Atherogenesis, cardiovascular disease | GOLM1 KO mouse; macrophage-specific KO |
| TREM2 | Atherosclerosis, foam cell formation | TREM2 KO mouse; macrophage overexpression |
| MAT1A | Hepatocellular carcinoma, liver metabolism | MAT1A KO mouse; liver-specific overexpression |
Atherosclerosis and cardiovascular disease
Accelerated LDLR catabolism reduces hepatic LDL clearance, leading to elevated plasma LDL cholesterol and atherosclerosis. Ablation of plasma prekallikrein stabilizes LDLR, lowers LDL cholesterol, and protects against atherosclerosis in mice. GOLM1 promotes atherogenesis by activating EGFR-ERK signaling, which may enhance LDLR degradation. Macrophage scavenger receptors TREM2 and SCARF1 contribute to foam cell formation, a hallmark of atherosclerotic plaques.
Metabolic-associated fatty liver disease (MAFLD)
Protocatechuic acid protects against MAFLD, and this protection is associated with modulation of lipid metabolism genes, including those involved in LDLR turnover. Dysregulated LDLR catabolism may contribute to hepatic lipid accumulation and steatosis.
Hepatocellular carcinoma
Deregulation of methionine adenosyltransferases (MAT1A and MAT2A) has pleiotropic effects on lipid metabolism and is a determinant of liver cancer progression and prognosis. Altered LDLR catabolism may support cancer cell growth by affecting cholesterol availability.
From positive regulation of low-density lipoprotein particle receptor catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X promote LDLR degradation? | CRISPR knockout of gene X in HepG2 or primary hepatocytes, followed by LDLR immunoblot |
| Does a point mutation in LDLR alter its catabolic rate? | CRISPR point mutation knock-in of LDLR variants in cell lines |
| Does overexpression of gene Y accelerate LDLR catabolism? | Lentiviral overexpression of gene Y in hepatocytes, measure LDLR half-life |
| Does a tagged LDLR knock-in report real-time trafficking? | CRISPR knock-in of fluorescent tag (e.g., GFP) into LDLR locus |
| Does gene Z regulate LDLR catabolism in vivo? | Liver-specific CRISPR knockout or overexpression in mice, measure plasma LDL |
| Can a miRNA mimic alter LDLR catabolism? | Transfection of miR-127-3p mimic in macrophages, assess LDLR levels |
How to Study the positive regulation of low-density lipoprotein particle receptor catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Genes affecting LDLR surface levels | Identify positive regulators of LDLR catabolism |
| Immunoblot | LDLR protein levels and half-life | Validate catabolism changes |
| Flow cytometry | Surface LDLR and LDL uptake | Quantify receptor availability |
| Live-cell imaging | LDLR trafficking and lysosomal delivery | Visualize catabolic steps |
| RNA-seq | Transcriptional changes in lipid pathways | Global response to perturbations |
| Proteomics | Protein interactions and modifications | Discover regulatory complexes |
| Cycloheximide chase | LDLR degradation rate | Measure catabolic flux |
| miRNA mimic/inhibitor | Post-transcriptional regulation | Study miR-127-3p effects |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss alters LDLR catabolism. Cells are infected with a lentiviral sgRNA library, selected, and LDLR surface levels are measured by flow cytometry or immunoblot. Hits are validated individually.
Proteomics and immunoblotting
LDLR protein half-life is measured by cycloheximide chase followed by immunoblot. Proteomic approaches can identify interacting partners and post-translational modifications that regulate catabolism.
Imaging and trafficking assays
Fluorescently tagged LDLR (e.g., GFP-LDLR) allows live-cell imaging of endocytosis, recycling, and lysosomal delivery. Co-localization with lysosomal markers (LAMP1) indicates degradation.
RNA-seq and miRNA profiling
Transcriptomic analysis after genetic perturbation reveals changes in lipid metabolism pathways. miRNA mimics or inhibitors can be used to study post-transcriptional regulation of LDLR catabolism.
How CRISPR Can Be Used to Study GO:0032805 positive regulation of low-density lipoprotein particle receptor catabolic process
Knockout
CRISPR knockout of candidate genes (e.g., KLKB1, GOLM1) in hepatocytes or macrophages can determine whether they are required for LDLR catabolism. Loss of PK stabilizes LDLR and lowers LDL cholesterol. GOLM1 knockout reduces atherogenesis in mice.
Point Mutation
Point mutations in LDLR or regulatory proteins can be introduced to mimic human variants. For example, mutations affecting the LDLR cytoplasmic tail alter endocytosis and degradation. CRISPR base editing enables precise single-nucleotide changes to study catabolic motifs.
Knock-in
Knock-in of fluorescent or affinity tags (e.g., GFP, HA) into the endogenous LDLR locus allows real-time tracking of receptor catabolism. This approach preserves native regulation and provides a tool for high-content imaging.
Overexpression
Overexpression of genes such as GOLM1 or TREM2 via lentiviral vectors can test whether increased levels accelerate LDLR degradation. Overexpression of PK may enhance catabolism, while its absence stabilizes LDLR.
How EDITGENE Supports positive regulation of low-density lipoprotein particle receptor catabolic process Research
Researchers studying positive regulation of low-density lipoprotein particle receptor catabolic process-related genes often need to determine whether a candidate gene is causally involved in LDLR turnover, and to dissect the precise molecular steps. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of low-density lipoprotein particle receptor catabolic process research.
Frequently Asked Questions About positive regulation of low-density lipoprotein particle receptor catabolic process
What is GO:0032805?
GO:0032805 is the Gene Ontology term for positive regulation of low-density lipoprotein particle receptor catabolic process, meaning any process that increases the breakdown of LDL receptors.
What genes are involved in positive regulation of LDL receptor catabolism?
Key genes include LDLR itself, KLKB1 (plasma prekallikrein), GOLM1, TREM2, and SCARF1, as shown in recent studies.
How does plasma prekallikrein affect LDL receptor degradation?
Plasma prekallikrein stabilizes LDLR; its ablation decreases LDLR degradation, lowers LDL cholesterol, and protects against atherosclerosis in mice.
What is the role of GOLM1 in atherosclerosis?
GOLM1 promotes atherogenesis by activating EGFR-ERK signaling, which can enhance LDLR catabolism and reduce LDL clearance.
How do TREM2 and SCARF1 influence LDL receptor catabolism?
TREM2 promotes cholesterol uptake and foam cell formation in macrophages, while SCARF1 interacts with lipoproteins, both affecting receptor turnover.
What diseases are linked to LDL receptor catabolism?
Atherosclerosis, metabolic-associated fatty liver disease, and hepatocellular carcinoma are associated with altered LDLR catabolism.
What experimental models are used to study GO:0032805?
CRISPR knockout, point mutation, knock-in, and overexpression models in hepatocytes and macrophages, combined with immunoblot, imaging, and RNA-seq.
How can CRISPR screens identify regulators of LDL receptor catabolism?
Pooled sgRNA libraries can be used to knock out genes genome-wide, followed by selection and measurement of LDLR surface levels to find positive regulators.
What is the connection between miR-127-3p and LDL receptor catabolism?
miR-127-3p alters macrophage fatty acid profiles and oxidative phosphorylation, indirectly influencing lipid handling and potentially LDLR catabolism.
Why is positive regulation of LDL receptor catabolism a therapeutic target?
Inhibiting LDLR degradation can lower plasma LDL cholesterol and reduce atherosclerosis, as demonstrated by PK ablation studies.
Conclusion
GO:0032805, positive regulation of low-density lipoprotein particle receptor catabolic process, is a central node in cholesterol homeostasis. The balance between LDLR synthesis and degradation determines plasma LDL levels and cardiovascular risk. Recent studies have identified plasma prekallikrein, GOLM1, TREM2, and SCARF1 as key modulators of this process, linking it to atherosclerosis, MAFLD, and liver cancer. CRISPR-based models and multi-omics approaches are powerful tools to dissect the underlying mechanisms and to discover new therapeutic targets. EDITGENE offers comprehensive services to support this research.
References
- 1. Wang Y et al.. 2024. Structure of scavenger receptor SCARF1 and its interaction with lipoproteins.. Elife 13 PMID: 39541158
- 2. Guo X et al.. 2023. TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis.. Cell Mol Life Sci 80(5):137 PMID: 37133566
- 3. Tan J et al.. 2023. Protection against Metabolic Associated Fatty Liver Disease by Protocatechuic Acid.. Gut Microbes 15(1):2238959 PMID: 37505920
- 4. Gai X et al.. 2025. GOLM1 Promotes Atherogenesis by Activating Macrophage EGFR-ERK Signaling Cascade.. Circ Res 136(8):848-861 PMID: 40026146
- 5. Wang JK et al.. 2022. Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis.. Circulation 145(9):675-687 PMID: 35189703
- 6. Frau M et al.. 2013. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.. J Hepatol 59(4):830-41 PMID: 23665184
- 7. Liu Y et al.. 2024. MiR-127-3p enhances macrophagic proliferation via disturbing fatty acid profiles and oxidative phosphorylation in atherosclerosis.. J Mol Cell Cardiol 193:36-52 PMID: 38795767
- 8. Hussain MM et al.. 1999. The mammalian low-density lipoprotein receptor family.. Annu Rev Nutr 19:141-72 PMID: 10448520
